Phase 1 to Evaluate the Safety and Pharmacokinetic Durg-drug Interaction of YYC506-T and YYC506-A
Latest Information Update: 10 May 2021
At a glance
- Drugs YYC 506 (Primary)
- Indications Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors Yooyoung Pharmaceutical
- 04 May 2021 Status changed from planning to completed.
- 04 May 2021 New trial record